First and Only Extended-Release Prescription Sleep Medication Indicated for Sleep Induction and Maintenance Covers Broad Insomnia Population

Paris, France, September 6, 2005 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved AMBIEN CR™ (zolpidem tartrate extended-release tablets) CIV, a new extended-release formulation of the number one prescription sleep aid, AMBIEN® (zolpidem tartrate) CIV, for the treatment of insomnia. AMBIEN CR is non-narcotic and a non-benzodiazepine, formulated to offer a similar safety profile to AMBIEN with a new indication for sleep maintenance, in addition to sleep induction.

For fullstendig pressemelding, se vedlagt pdf-fil.